Skip to main content
. 2021 Sep 16;72:103587. doi: 10.1016/j.ebiom.2021.103587

Table 3.

The occurrence of adverse events in B-ACT group was low and pharyngeal discomfort was more common in younger patients.

B-ACT related adverse events All Age
Sex
<65 years ≥65 years p Female Male p
N 141 104 37 93 48
Nausea 8 (5·7%) 6 (5·8%) 2 (5·4%) 0·94 6 (5·8%) 2 (5·4%) 0·94
Chest discomfort 15 (10·6%) 12 (11·5%) 3 (8·1%) 0·56 7 (7·5%) 8 (16·7%) 0·095
Pharyngeal discomfort 46 (32·6%) 39 (37·5%) 7 (18·9%) 0·038 29 (31·2%) 17 (35·4%) 0·61
Fever 5 (3·6%) 4 (3·9%) 1 (2·7%) 0·75 2 (2·2%) 3 (6·3%) 0·21
Blood in sputum 15 (10·6%) 12 (11·5%) 3 (8·1%) 0·56 10 (10·8%) 5 (10·4%) 0·95

Data are summarized as n (percentage) for categorical data. Categorical variables were compared by chi-square test. Statistical significance was considered when the two-tailed P < 0·05. ACT, Airway Clearance Therapy; B, Bronchoscopic.